Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 25, 2014

Key Technologies Highlighted as Late-Breakers at ACC.14

By Dave Fornell, DAIC editor

Data from several cutting-edge device clinical trials will be presented as late-breakers at the American College of Cardiology 63rd Annual Scientific Session & Expo (ACC.14), March 28-31.  

One of the most anticipated therapies on the interventional front is the use of renal denervation to treat drug resistant hypertension. However, its future was called into question recently when Medtronic announced it failed to meet the primary endpoints in its SYMPLICITY HTN-3 U.S. pivotal trial. The results of that trial will be presented at ACC on Saturday. Experts say this is not the end of the story, and additional data might be revealed in another late-breaker with data from the Global SYMPLICITY Registry. 

Also on the interventional front, the NEXT trial is among the first to compare a biodegradable polymer drug-eluting stent (DES) with a durable polymer DES. 

In electrophysiology, the use of cardiac resynchronization therapy (CRT) devices was expanded a few years ago to patients with mild heart failure. One of the late breakers will discuss long-term survival in this CRT population.

In structural heart, three key presentations are featured. The CHOICE Trial will compare self-expanding (Medtronic’s Corevalve) to balloon expandable (Edwards’ Sapien) TAVR devices. Another compares the Corevalve with surgical outcomes in patients deemed high risk for surgery. The final session will share one-year outcomes from the STS/ACC Transcatheter Valve Therapy Registry.

Complete list of ACC late-breaking trials

For information on ACC.14, the official site is accscientificsession.cardiosource.org 

Related Content

Sci-image, Scimage, CVIS, CIIMS, Cpacs c-pacs, cardiovascular information system

Today's cardiovascular information systems need to incorporate all facets of the cardiology department, including subspecialties, to allow a complete picture of a patient's record. These data also need to be able to be shared with enterprise data systems, such as the electronic medical record (EMR). This image is from ScImage, illustrating the various aspects that integrate to make up a complete CVIS. 

 

Feature | September 29, 2016 | Val Kapitula, RT(R), PMP, CIIP
Cardiovascular Information and Imaging Systems (CVIS) have existed for many years in the dedicated sub-specialty area
Keystone Heart, TriGuard Embolic Protection Device, real-world results, PCR London Valves Conference 2016
News | Embolic Protection Devices| September 29, 2016
Keystone Heart Ltd. recently announced the safety and efficacy of the TriGuard Cerebral Embolic Protection device...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
Infinix 4D CT

Toshiba's Infinix 4D CT, which combines CT with angiography in the interventional lab.

Feature | Angiography| September 28, 2016 | Tom Watson BS, RCVT, Clinical Analyst, MD Buyline
One of the more significant advancements for interventional X-ray (IXR) in the past few years has been a significantl
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) has announced the 11 late-breaking trials and 16 fi
Avinger, U.S. Department of Veterans Affairs, VA, Lumivascular technology, FSS Contract Award
News | Optical Coherence Tomography (OCT)| September 27, 2016
Avinger Inc. recently announced the company has received an FSS Contract Award from the U.S. Department of Veterans...
European Heart Rhythm Association, EHRA White Book 2016, EP Europace supplement, cardiac rhythm device use, Europe
News | EP Lab| September 27, 2016
In August, the European Heart Rhythm Association (EHRA) and EP Europace journal announced the release of the supplement...
News | Pharmaceuticals| September 26, 2016
Nearly 2 out of 5 people with diabetes who could benefit from statin therapy to lower their risk of future heart attack...
Bard, Lutonix 014 DCB, drug-coated balloon, six-month endpoint, FDA IDE trial
Technology | Drug-Eluting Balloons| September 26, 2016
C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE...
smartphones, hospital tranfers, heart attack patients, JACC study, South Korea
News | Mobile Devices| September 23, 2016
Smartphone communication among medical teams at different hospitals can significantly reduce the time it takes for...
Overlay Init